Cargando…

Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications

Palmitoylethanolamide (PEA), the naturally occurring amide of ethanolamine and palmitic acid, is an endogenous lipid compound endowed with a plethora of pharmacological functions, including analgesic, neuroprotective, immune-modulating, and anti-inflammatory effects. Although the properties of PEA w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valenza, Marta, Facchinetti, Roberta, Steardo, Luca, Scuderi, Caterina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496237/ https://www.ncbi.nlm.nih.gov/pubmed/36139030 http://dx.doi.org/10.3390/biom12091191

Ejemplares similares

Looking for a Treatment for the Early Stage of Alzheimer’s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin
por: Facchinetti, Roberta, et al.
Publicado: (2020)

Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer’s Disease
por: Facchinetti, Roberta, et al.
Publicado: (2022)

Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2018)

Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
por: Valenza, Marta, et al.
Publicado: (2021)

Altered Waste Disposal System in Aging and Alzheimer’s Disease: Focus on Astrocytic Aquaporin-4
por: Valenza, Marta, et al.
Publicado: (2020)

Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide
por: Scuderi, Caterina, et al.
Publicado: (2011)

Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α
por: Scuderi, Caterina, et al.
Publicado: (2012)

Astrocyte Function Is Affected by Aging and Not Alzheimer’s Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2019)

Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects
por: Scuderi, Caterina, et al.
Publicado: (2018)

Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease
por: Scuderi, C, et al.
Publicado: (2014)

Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders
por: Valenza, Marta, et al.
Publicado: (2021)

Astrocytes and the Psychiatric Sequelae of COVID-19: What We Learned from the Pandemic
por: Steardo, Luca, et al.
Publicado: (2022)

Neuroglia in the autistic brain: evidence from a preclinical model
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2018)

Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention
por: Scuderi, Caterina, et al.
Publicado: (2021)

Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease
por: Bellanti, Francesco, et al.
Publicado: (2022)

Targeting neuroinflammation in Alzheimer’s disease
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2016)

HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia
por: Sarnelli, Giovanni, et al.
Publicado: (2018)

The Basal Pharmacology of Palmitoylethanolamide
por: Rankin, Linda, et al.
Publicado: (2020)

How useful are biomarkers for the diagnosis of Alzheimer’s disease and especially for its therapy?
por: Valenza, Marta, et al.
Publicado: (2022)

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
por: Beggiato, Sarah, et al.
Publicado: (2019)

Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes
por: Steardo, Luca, et al.
Publicado: (2015)

Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
por: Esposito, Giuseppe, et al.
Publicado: (2011)

Changes at glutamate tripartite synapses in the prefrontal cortex of a new animal model of resilience/vulnerability to acute stress
por: Bonifacino, Tiziana, et al.
Publicado: (2023)

Differential Cannabinoid Receptor Expression during Reactive Gliosis: a Possible Implication for a Nonpsychotropic Neuroprotection
por: De Filippis, Daniele, et al.
Publicado: (2009)

Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders
por: Assogna, Martina, et al.
Publicado: (2022)

Oral Adelmidrol Administration Up-Regulates Palmitoylethanolamide Production in Mice Colon and Duodenum through a PPAR-γ Independent Action
por: Del Re, Alessandro, et al.
Publicado: (2022)

Targeting the Oxytocinergic System: A Possible Pharmacological Strategy for the Treatment of Inflammation Occurring in Different Chronic Diseases
por: Friuli, Marzia, et al.
Publicado: (2021)

Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy
por: Gabrielsson, Linda, et al.
Publicado: (2016)

Palmitoylethanolamide: A Natural Compound for Health Management
por: Clayton, Paul, et al.
Publicado: (2021)

Editorial: Immune Mechanisms in white matter lesions: Clinical and pathophysiological implications
por: Pang, Xiao-Wei, et al.
Publicado: (2023)

Palmitoylethanolamide Promotes White-to-Beige Conversion and Metabolic Reprogramming of Adipocytes: Contribution of PPAR-α
por: Annunziata, Chiara, et al.
Publicado: (2022)

Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review
por: Steardo, Luca, et al.
Publicado: (2021)

Co-micronized Palmitoylethanolamide/Polydatin Treatment Causes Endometriotic Lesion Regression in a Rodent Model of Surgically Induced Endometriosis
por: Di Paola, Rosanna, et al.
Publicado: (2016)

Delay of Morphine Tolerance by Palmitoylethanolamide
por: Di Cesare Mannelli, Lorenzo, et al.
Publicado: (2015)

S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells
por: Esposito, Giuseppe, et al.
Publicado: (2008)

Multiple Factors Involved in the Pathogenesis of White Matter Lesions
por: Lin, Jing, et al.
Publicado: (2017)

Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence
por: Bortoletto, Riccardo, et al.
Publicado: (2022)

Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence
por: Colizzi, Marco, et al.
Publicado: (2021)

Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence
por: Colizzi, Marco, et al.
Publicado: (2022)

Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review
por: Passavanti, Maria Beatrice, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fnie9s39ug0bgqjf9qpnjlcimn